Overview

Drug Screening Market is valued at USD 6130.10 million in 2022 and is projected to reach a value of over USD 15000 million by the end of 2028, and register a CAGR of 17% during the forecast period.

There has been a rise in the comsumption of unprescribed drugs and alcohol worldwide. As per the report published by the United Nations Office on Drugs and Crime (UNODC) 2015,  over 5% of the global adult population has at least tried drugs once in their lifetime. Furthermore, over 0.6% of the total adult population across the world suffer from drug abuse disorder. Owing to these statictics, the drug screening market is esimated to showcase substantial growth over the forecasted timeframe.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Drug Screening Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of Drug Screening Market.

According to the research study conducted by FutureWise research analysts, the Drug Screening Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

Major players included in the Drug Screening Market are:

• Abbott
• Dragerwerk
• Labcorp
• Quest Diagnostics
• Alfa Scientific Designs
• Lifeloc
• MPD Inc.
• Orasure
• Omega Laboratories
• Premier Biotech
• Psychemedics
• Roche
• Shimadzu
• Siemens Healthineers 
• Thermo Fisher Scientific

(Note: The list of the major players will be updated with the latest market scenario and trends)

Drug Screening Market Segmentation:

By Product Type

• Analytical Instruments
   o Immunoassay Analyzers
   o Chromatography Instruments
   o Breathalyzers
        o Fuel Cell Breathalyzers
        o Semiconductor Breathalyzers
        o Other Breathalyzers
• Rapid Testing Devices
   o Urine Testing Devices
       o Drug Testing Cups
       o DIP Cards
       o Drug Testing Cassettes
   o Oral Fluid Testing Devices
• Consumables
   o Assay Kits
   o Sample Collection Devices
   o Calibrators and Controls
   o Other Consumables

By Drug Screening Services

• Regulated
• Non-Regulated

By Sample Type

• Urine Samples
• Breath Samples
• Oral Fluid Samples
• Hair Samples
• Other Samples

By End-user

• Workplace
• Criminal Justice Systems and Law Enforcement Agencies
• Drug Treatment Centers
• Pain Management Centers
• Schools and Colleges
• Hospitals
• Individual Users
• Drug Testing Laboratories

By Region

• North America
• Latin America
• Europe
• Asia-Pacific
• Middle East and Africa

Competitive Landscape:

• Tier 1 players- established companies in the market with a major market share
• Tier 2 players
• Emerging players which are growing rapidly
• New Entrants

FutureWise Key Takeaways:

• Growth prospects
• SWOT analysis
• Key trends
• Key data-points affecting market growth

Objectives of the Study:

• To provide with an exhaustive analysis on the Drug Screening Market By Product Type, By Drug Screening Services, By Sample Type, By End User and By Region.
• To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
• To evaluate and forecast micro-markets and the overall market
• To predict the market size, in key regions— North America, Europe, Asia Pacific and Middle East and Africa
• To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

Flexible Delivery Model:

• We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
• The customization Mobility Care offered are free of charge with the purchase of any license of the report
• You can directly share your requirements/changes to the current table of content to sales@futurewiseresearch.com

Table of Contents

1. Market Introduction
   1.1. Objectives of the Study 
   1.2. Market Definition 
   1.3. Market Scope 
        1.3.1. Years Considered for the Study
        1.3.2. Market Covered
   1.4. Currency 
   1.5. Limitations 
   1.6. Stakeholders 

2. Research Methodology 
   2.1. Research Data 
        2.1.1. Secondary Data
               2.1.1.1. Key Data from Secondary Sources
        2.1.2. Primary Data
               2.1.2.1. Key Data from Primary Sources
   2.2. Market Size Estimation 
   2.3. Market Breakdown and Data Triangulation 
   2.4. Assumptions for the Study  

3. Executive Summary
   3.1. Market Outlook
   3.2. Segment Outlook
   3.3. Competitive Insights

4. Drug Screening Market Variables, Trends & Scope
   4.1. Market Lineage Outlook
   4.2. Penetration and Growth Prospect Mapping
   4.3. Industry Value Chain Analysis
   4.4. Cost Analysis Breakdown
   4.5. Technology Overview
   4.6. Regulatory Framework
        4.6.1. Reimbursement Framework
        4.6.2. Standards and Compliances

5. Market Overview
   5.1. Market Dynamics
        5.1.1. Market Driver Analysis
               5.1.1.1. Increasing focus of Drug Screening Market Companies on Brand Protection
               5.1.1.2. Untapped Opportunities in Emerging Regions
        5.1.2. Market Restraint Analysis
               5.1.2.1. High Cost Associated with Implementation of Predictive Analysis
        5.1.3. Industry Challenges
               5.1.3.1. Presence of Ambiguous Regulatory Framework

6. Drug Screening Market Analysis Tools
   6.1. Industry Analysis - Porter’s
        6.1.1. Supplier Power
        6.1.2. Buyer Power
        6.1.3. Substitution Threat
        6.1.4. Threat from New Entrants
        6.1.5. Competitive Rivalry
   6.2. Pestel Analysis
        6.2.1. Political Landscape
        6.2.2. Environmental Landscape
        6.2.3. Social Landscape
        6.2.4. Technology Landscape
        6.2.5. Legal Landscape
   6.3. Major Deals And Strategic Alliances Analysis
        6.3.1. Joint Ventures
        6.3.2. Mergers and Acquisitions
        6.3.3. Licensing and Partnership
        6.3.4. Technology Collaborations
        6.3.5. Strategic Divestments
   6.4. Market Entry Strategies
   6.5. Case Studies

7. Drug Screening Market, By Product Type Historical Analysis and Forecast 2022-2028 (USD Million)
   7.1. Analytical Instruments
        7.1.1. Immunoassay Analyzers
        7.1.2. Chromatography Instruments
        7.1.3. Breathalyzers
               7.1.3.1. Fuel Cell Breathalyzers
               7.1.3.2. Semiconductor Breathalyzers
               7.1.3.3. Other Breathalyzers
   7.2. Rapid Testing Devices
        7.2.1. Urine Testing Devices
               7.2.1.1. Drug Testing Cups
               7.2.1.2. DIP Cards
               7.2.1.3. Drug Testing Cassettes
        7.2.2. Oral Fluid Testing Devices  
   7.3. Consumables
        7.3.1. Assay Kits
        7.3.2. Sample Collection Devices
        7.3.3. Calibrators and Controls
        7.3.4. Other Consumables

8. Drug Screening Market, By Drug Screening Services Historical Analysis and Forecast 2022-2028 (USD Million)  
   8.1. Regulated
   8.2. Non-Regulated

9. Drug Screening Market, By Sample Type Historical Analysis and Forecast 2022-2028 (USD Million)  
   9.1. Urine Samples
   9.2. Breath Samples
   9.3. Oral Fluid Samples
   9.4. Hair Samples
   9.5. Other Samples

10. Drug Screening Market, By End User Historical Analysis and Forecast 2022-2028 (USD Million)  
    10.1. Workplace
    10.2. Criminal Justice Systems and Law Enforcement Agencies
    10.3. Drug Treatment Centers
    10.4. Pain Management Centers
    10.5. Schools and Colleges
    10.6. Hospitals
    10.7. Individual Users
    10.8. Drug Testing Laboratories

11. North America Drug Screening Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    11.1. Introduction
    11.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          11.2.1. U.S.A
          11.2.2. Canada
          11.2.3. Mexico
    11.3. Market Size (USD Million) Forecast for North America 2022-2028

12. Latin America Drug Screening Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    12.1. Introduction
    12.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          12.2.1. Brazil
          12.2.2. Venezuela
          12.2.3. Argentina
          12.2.4. Rest of Latin America
    12.3. Market Size (USD Million) Forecast for Latin America 2022-2028

13. Europe Drug Screening Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    13.1. Introduction
    13.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          13.2.1. Germany
          13.2.2. U.K         
          13.2.3. France
          13.2.4. Italy
          13.2.5. Spain
          13.2.6. Russia
          13.2.7. Poland
          13.2.8. Rest of Europe
    13.3. Market Size (USD Million) Forecast for Europe 2022-2028

14. Asia Pacific Drug Screening Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    14.1. Introduction
    14.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          14.2.1. Japan
          14.2.2. China
          14.2.3. India
          14.2.4. Australia and New Zealand
          14.2.5. ASEAN
          14.2.6. Rest of Asia Pacific
    14.3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028  

15. Middle East and Africa Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    15.1. Introduction
    15.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          15.2.1. GCC
          15.2.2. Israel
          15.2.3. South Africa
          15.2.4. Rest of MEA
    15.3. Market Size (USD Million) Forecast for MEA 2022-2028

16. Market Share Analysis and Competitive Landscape   
    16.1. Global Landscape - Key Players, Revenue and Presence
    16.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
    16.3. Global Emerging Companies
    16.4. North America - Market Share Analysis and Key Regional Players
    16.5. Europe - Market Share Analysis and Key Regional Players
    16.6. Asia Pacific - Market Share Analysis and Key Regional Players
    16.7. Global Key Player - Growth Matrix

17. Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    17.1. Abbott
          17.1.1. Company Overview
          17.1.2. Product Portfolio
          17.1.3. SWOT Analysis
          17.1.4. Financial Overview
          17.1.5. Strategic Overview
    17.2. Dragerwerk
          17.2.1. Company Overview
          17.2.2. Product Portfolio
          17.2.3. SWOT Analysis
          17.2.4. Financial Overview
          17.2.5. Strategic Overview 
    17.3. Labcorp
          17.3.1. Company Overview
          17.3.2. Product Portfolio
          17.3.3. SWOT Analysis
          17.3.4. Financial Overview
          17.3.5. Strategic Overview
    17.4. Quest Diagnostics
          17.4.1. Company Overview
          17.4.2. Product Portfolio
          17.4.3. SWOT Analysis
          17.4.4. Financial Overview
          17.4.5. Strategic Overview
    17.5. Alfa Scientific Designs
          17.5.1. Company Overview
          17.5.2. Product Portfolio
          17.5.3. SWOT Analysis
          17.5.4. Financial Overview
          17.5.5. Strategic Overview          
    17.6. Lifeloc
          17.6.1. Company Overview
          17.6.2. Product Portfolio
          17.6.3. SWOT Analysis
          17.6.4. Financial Overview
          17.6.5. Strategic Overview      
    17.7. MPD Inc.
          17.7.1. Company Overview
          17.7.2. Product Portfolio
          17.7.3. SWOT Analysis
          17.7.4. Financial Overview
          17.7.5. Strategic Overview
    17.8. Orasure
          17.8.1. Company Overview
          17.8.2. Product Portfolio
          17.8.3. SWOT Analysis
          17.8.4. Financial Overview
          17.8.5. Strategic Overview 
    17.9. Omega Laboratories
          17.9.1. Company Overview
          17.9.2. Product Portfolio
          17.9.3. SWOT Analysis
          17.9.4. Financial Overview
          17.9.5. Strategic Overview 
    17.10.Premier Biotech
          17.10.1. Company Overview
          17.10.2. Product Portfolio
          17.10.3. SWOT Analysis
          17.10.4. Financial Overview
          17.10.5. Strategic Overview
    17.11.Psychemedics
          17.11.1. Company Overview
          17.11.2. Product Portfolio
          17.11.3. SWOT Analysis
          17.11.4. Financial Overview
          17.11.5. Strategic Overview          
    17.12.Roche
          17.12.1. Company Overview
          17.12.2. Product Portfolio
          17.12.3. SWOT Analysis
          17.12.4. Financial Overview
          17.12.5. Strategic Overview      
    17.13.Shimadzu
          17.13.1. Company Overview
          17.13.2. Product Portfolio
          17.13.3. SWOT Analysis
          17.13.4. Financial Overview
          17.13.5. Strategic Overview
    17.14.Siemens Healthineers
          17.14.1. Company Overview
          17.14.2. Product Portfolio
          17.14.3. SWOT Analysis
          17.14.4. Financial Overview
          17.14.5. Strategic Overview
    17.15.Thermo Fisher Scientific
          17.15.1. Company Overview
          17.15.2. Product Portfolio
          17.15.3. SWOT Analysis
          17.15.4. Financial Overview
          17.15.5. Strategic Overview

18. Pre and Post COVID-19 Impact
    18.1. Positive influence on the healthcare industry
    18.2. The financial disruption of the manufacturing sector
    18.3. Impact of COVID-19 on emerging companies
    18.4. Significant mandates in the healthcare regulations initiated by administrations
    18.5. The overall economic slowdown of the developing and developed nations

19. FutureWise SME Key Takeaway Points for Client

Tables

Figures